# Applying the Agent Metadata Specification to the Pharmaceuticals Industry – Sales Engagement Planning

## Introduction

The cross-industry Agent Metadata Specification is published [here](https://github.com/TavroOrg/Agent-Metadata-Specification/tree/main/assets/Publications). This section provides an example that combines all the relevant artifacts for the pharmaceuticals industry.

## Conceptual Model

An overall conceptual model for the use case is shown in Figure 1.

<p align="center">
  <img src="../assets/images/Pharmaceuticals – Sales Engagement Planning Assistant.png" alt="Pharmaceuticals – Sales Engagement Planning Assistant" width="600">
  <br>
  <em>Figure 1: Conceptual model for sales engagement planning for the pharmaceuticals industry</em>
</p>

This example covers the following artifacts (see Table 1):

<table align="center">
  <thead>
    <tr>
      <th><b>Artifact</b></th>
      <th><b>Description</b></th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>1. AI Use Case</td>
      <td><ul><li>Sales Engagement Planning Assistant</li></ul></td>
    </tr>
    <tr>
      <td>2. Agent</td>
      <td><ul><li>Sales Engagement Planning Agent</li></ul></td>
    </tr>
    <tr>
      <td>3. Data Sources</td>
      <td><ul><li>sales_engagement_data Table</li></ul></td>
    </tr>
    <tr>
      <td>4. Tools</td>
      <td>
        <ul>
          <li>Physician Profile Lookup Tool</li>
          <li>Prescribing History Analysis Tool</li>
          <li>Formulary Coverage Query Tool</li>
        </ul>
      </td>
    </tr>
    <tr>
      <td>5. Applications</td>
      <td>
        <ul>
          <li>CRM Platform</li>
          <li>Medical Information Portal</li>
        </ul>
      </td>
    </tr>
    <tr>
      <td>6. Business Processes</td>
      <td><ul><li>Pharmaceutical Sales Engagement</li></ul></td>
    </tr>
    <tr>
      <td>7. Regulations</td>
      <td>
        <ul>
          <li>FDA 21 CFR Part 202 - Prescription Drug Advertising</li>
          <li>PhRMA Code on Interactions with Healthcare Professionals</li>
        </ul>
      </td>
    </tr>
    <tr>
      <td>8. Agent Risk Assessments</td>
      <td>
        <ul>
          <li>Regulatory Risk Assessment</li>
          <li>Cybersecurity Risk Assessment</li>
          <li>Data Risk Assessment</li>
        </ul>
      </td>
    </tr>
  </tbody>
</table>

<p align="center">
  <em>Table 1: Agent metadata artifacts for sales engagement planning for the pharmaceuticals industry</em>
</p>

### 1. AI Use Case - Sales Engagement Planning Assistant

This AI use case leverages commercial engagement records, prescribing history, payer formulary data, and validated clinical evidence to generate data-driven insights that guide sales representatives toward informed, compliant, and targeted discussions. The expected benefits include improved engagement quality, reduced off-label promotion risk, stronger compliance adherence, and more efficient use of sales representative time - ultimately supporting improved patient outcomes through more appropriate prescribing patterns.

### 2. Agent - Sales Engagement Planning

The **Sales Engagement Planning Agent** assists pharmaceutical sales representatives in planning calls and visits with healthcare providers. The agent ingests and analyzes commercial, clinical, and engagement data to produce structured, compliant pre-call summaries covering prescribing patterns, formulary considerations, clinical updates, and compliance checkpoints.

The agent follows a strict eight-step workflow:

- Step 1 - Retrieve Engagement Context: Gather physician profile and specialty, previous sales interactions, prescribing history and trends, payer formulary coverage, recent clinical studies, and treatment guidelines. Flag missing information before proceeding.

- Step 2 - Validate Data Quality: Check for outdated prescribing data, missing physician profile details, conflicting payer information, or incomplete engagement history. Flag inconsistencies.

- Step 3 - Analyze Physician Engagement Patterns: Evaluate historical interactions and prescribing behavior within therapeutic areas. Avoid assumptions beyond available evidence.

- Step 4 - Review Clinical and Market Context: Analyze newly published clinical studies, guideline updates, formulary changes, and competitive landscape. Only reference validated and approved clinical information.

- Step 5 - Generate Engagement Insights: Produce recommended discussion themes, clinical updates, formulary considerations, and insights aligned with physician specialty and interests.

- Step 6 - Identify Risks or Compliance Considerations: Flag off-label discussion risks, outdated clinical references, incomplete data sources, and payer restrictions.

- Step 7 - Generate Recommendations: Summarize physician context, prescribing insights, recommended preparation points, and compliance considerations. Do not generate promotional claims beyond approved drug labeling.

- Step 8 - Human Review Safeguard: Explicitly state that all results require sales representative review and validation before use in any physician interaction.

Core behavioral rules include: never generating off-label promotional claims, only referencing approved drug indications, not fabricating prescribing or payer data, maintaining confidentiality of physician and patient data, and always distinguishing data-driven insights from inferred recommendations.

### 3. Data Source - sales_engagement_data Table

The agent accesses the sales_engagement_data table, which contains historical and current pharmaceutical sales engagement records (see Table 2). The agent reads the following columns:

<table align="center">
  <thead>
    <tr>
      <th><b>Column Name</b></th>
      <th><b>Description</b></th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>physician_id</td>
      <td>Unique identifier for the healthcare provider</td>
    </tr>
    <tr>
      <td>physician_name</td>
      <td>Full name of the physician</td>
    </tr>
    <tr>
      <td>physician_specialty</td>
      <td>Clinical specialty of the healthcare provider</td>
    </tr>
    <tr>
      <td>sales_representative_id</td>
      <td>Identifier of the assigned sales representative</td>
    </tr>
    <tr>
      <td>drug_name</td>
      <td>Name of the pharmaceutical product discussed</td>
    </tr>
    <tr>
      <td>interaction_type</td>
      <td>Type of engagement (call, visit, webinar, etc.)</td>
    </tr>
    <tr>
      <td>engagement_date</td>
      <td>Date of the sales interaction</td>
    </tr>
  </tbody>
</table>

<p align="center">
  <em>Table 2: Sample columns in the sales_engagement_data table</em>
</p>

### 4. Tools

The Sales Engagement Planning Agent uses the following tools (see Table 3):

<table align="center">
  <thead>
    <tr>
      <th><b>Tool</b></th>
      <th><b>Description</b></th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Physician Profile Lookup Tool</td>
      <td>Retrieves specialty, affiliation, and engagement history for a given physician. Enables the agent to personalize pre-call insights based on the physician's clinical focus and prior interaction history with the sales team.</td>
    </tr>
    <tr>
      <td>Prescribing History Analysis Tool</td>
      <td>Queries prescribing trend data for a specified physician and therapeutic area. Provides prescribing volume, brand vs. competitor share, and recent prescription trajectory to identify engagement opportunities.</td>
    </tr>
    <tr>
      <td>Formulary Coverage Query Tool</td>
      <td>Retrieves payer formulary status and coverage tier information for promoted drugs. Surfaces reimbursement considerations that may influence a physician's prescribing decisions within their patient population.</td>
    </tr>
  </tbody>
</table>

<p align="center">
  <em>Table 3: Tools used by the sales engagement planning agent</em>
</p>

### 5. Applications – CRM Platform / Medical Information Portal

The following applications are accessed or utilized by the Sales Engagement Planning Agent (see Table 4):

<table align="center">
  <thead>
    <tr>
      <th><b>Tool</b></th>
      <th><b>Description</b></th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CRM Platform</td>
      <td>Stores physician contact records, historical interaction logs, and sales representative activity data. The agent reads engagement history and physician profile data from the CRM to inform pre-call preparation.</td>
    </tr>
    <tr>
      <td>Medical Information Portal</td>
      <td>An internally managed clinical reference platform providing access to approved drug labeling, validated clinical study summaries, and treatment guideline updates. Ensures all clinical insights remain grounded in approved, current information.</td>
    </tr>
  </tbody>
</table>

<p align="center">
  <em>Table 4: Applications used by the sales engagement planning agent</em>
</p>

### 6. Business Process

The agent is used by the **Pharmaceutical Sales Engagement** business process.

### 7. Regulations

The following regulations may govern this agent (see Table 5).

<table align="center">
  <thead>
    <tr>
      <th><b>Regulation</b></th>
      <th><b>Requirement</b></th>
      <th><b>Description</b></th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>FDA 21 CFR Part 202</td>
      <td>Prescription Drug Advertising</td>
      <td>Governs the promotion of prescription drugs, requiring that all promotional materials and interactions present a fair balance of risks and benefits and do not contain false or misleading claims. Agent outputs must remain within the bounds of approved labeling and must not generate off-label promotional content.</td>
    </tr>
    <tr>
      <td>PhRMA Code on Interactions with Healthcare Professionals</td>
      <td>Voluntary Industry Standard</td>
      <td>Establishes ethical standards for pharmaceutical company interactions with healthcare providers. The agent must ensure all engagement recommendations comply with PhRMA guidelines, particularly regarding the informational nature of sales interactions and prohibitions on improper inducements.</td>
    </tr>
  </tbody>
</table>

<p align="center">
  <em>Table 5: Regulations governing the AI use case and agent</em>
</p>

### 8. Agent Risk Assessment

The Agent Risk Assessment is broken down into three components:

#### 8.1 Regulatory Risk Assessment

The Sales Engagement Planning Agent operates within the highly regulated pharmaceutical promotional environment. Its outputs - pre-call engagement insights - directly influence how sales representatives interact with licensed healthcare professionals regarding prescription drug promotion. The agent is subject to **FDA 21 CFR Part 202** and industry conduct standards under the **PhRMA Code**. Any failure to constrain outputs to approved drug indications or fair-balance information could result in regulatory exposure. The agent carries a Medium-to-High regulatory risk classification due to the sensitivity of pharmaceutical promotional regulations and the potential impact of agent-generated content on physician prescribing.

#### 8.2 Cybersecurity Risk Assessment

The OWASP AI Vulnerability Scoring System (AIVSS) capability breakdown is 4.0/10 for the Sales Engagement Planning Agent reflects a constrained, deterministic design (see Table 6):

<table align="center">
  <thead>
    <tr>
      <th><b>Capability</b></th>
      <th><b>Score</b></th>
      <th><b>Summary</b></th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Autonomy of Action</td>
      <td>0.0</td>
      <td>Strictly step-by-step workflow; no autonomous execution</td>
    </tr>
    <tr>
      <td>Goal-Driven Planning</td>
      <td>0.5</td>
      <td>Multi-step task decomposition; no delegation capability</td>
    </tr>
    <tr>
      <td>Self-Modification</td>
      <td>0.0</td>
      <td>No ability to alter its own logic or instructions</td>
    </tr>
    <tr>
      <td>Dynamic Tool Use</td>
      <td>1.0</td>
      <td>Access to defined engagement data tools</td>
    </tr>
    <tr>
      <td>Memory Use</td>
      <td>1.0</td>
      <td>Some access to persistent memory mechanism documented</td>
    </tr>
    <tr>
      <td>Contextual Awareness</td>
      <td>1.0</td>
      <td>Extended context available</td>
    </tr>
    <tr>
      <td>Dynamic Identity</td>
      <td>0.0</td>
      <td>Static permissions; no role or identity changes</td>
    </tr>
    <tr>
      <td>Multi-Agent Interactions</td>
      <td>0.0</td>
      <td>No peer agent communication or delegation</td>
    </tr>
    <tr>
      <td>Non-Determinism</td>
      <td>0.5</td>
      <td>Fixed output format with natural language flexibility in insights</td>
    </tr>
    <tr>
      <td>Opacity &amp; Reflexivity</td>
      <td>0.0</td>
      <td>Fully auditable, stepwise output with explicit reasoning required</td>
    </tr>
  </tbody>
</table>

<p align="center">
  <em>Table 6: OWASP AIVSS capability breakdown</em>
</p>

#### 8.3 Data Risk Assessment

The agent accesses the sales_engagement_data table, which includes Physician Name, Physician ID, and Physician Specialty - fields that constitute Personally Identifiable Information (PII). The agent does not access Protected Health Information (PHI) or Payment Card Industry (PCI) data. Data governance controls must ensure physician identifiers are handled in accordance with applicable privacy regulations and that access is restricted to authorized sales personnel only.

#### 8.4 Overall Agent Risk Assessment

The Sales Engagement Planning Agent is a well-structured, single-purpose AI agent designed for pharmaceutical commercial engagement support. Its technical risk profile is low-to-medium: the agent executes a deterministic, step-by-step process, has no autonomous execution capability, accesses no PHI or PCI data, and mandates human review before any output is used in physician interactions.

The most significant risk dimensions are regulatory - specifically compliance with FDA prescription drug promotion rules and PhRMA ethical conduct standards - and data privacy, given the agent's access to physician PII. A secondary risk involves the potential for commercially motivated misuse, where agent-generated insights could be applied in ways that cross the line from information to promotion.

Governance focus should prioritize: (1) ensuring all agent-generated content remains within approved promotional boundaries, (2) confirming physician data is accessed only by authorized personnel, (3) consistently enforcing human oversight before insights are applied in sales engagements, and (4) maintaining clear audit trails of agent outputs for regulatory review purposes.

## Contributors

[Karan Dhawal, ZS Associates](https://www.linkedin.com/in/karandhawal/)

[Sunil Soares, Tavro AI](https://www.linkedin.com/in/sunilsoares/)
